Journal of Rheumatic Diseases

Table. 2.

Comparison of characteristics between non-progressors (ΔmSASSS <1 unit/year) and progressors (ΔmSASSS ≥1 unit/year)

Variable Non-progressor (n=66) Progressor (n=35) p-value
Age at disease onset (yr) 26.8±11.5 28.3±9.2 0.528
Age at estrogen sampling (yr) 36.3±11.6 42.6±8.5 0.006
Disease duration (mo) 37.1±38.4 78.4±87.5 0.011
Female 14 (21.2) 2 (5.7) 0.048
Peripheral arthritis 32 (48.5) 13 (37.1) 0.275
Hip involvement 17 (25.8) 4 (11.4) 0.123
Uveitis 18 (27.3) 9 (25.7) 0.866
Enthesitis 9 (13.6) 5 (14.3) 0.928
mSASSS, initial 3.8±4.5 16.3±13.4 <0.001
mSASSS, final 17.9±20.2 21.6±22.7 0.445
Sacroiliitis grade* 4.94±1.37 6.31±1.62 <0.001
Estrogen (pg/mL) 107.7±37.5 123.6±35.6 0.042
Dkk1 (ng/mL) 1,303.7±778.9 1,001.2±598.7 0.048
Leptin (pg/mL) 1,939.0±1,838.8 2,305.4±2,189.4 0.375
ESR, initial (mm/h) 49.1±35.4 61.0±27.3 0.087
CRP, initial (mg/dL) 2.31±2.75 4.21±4.37 0.024
BMI (kg/m2) 23.1±3.2 26.3±3.8 <0.001
Anti-TNF use 53 (80.3) 33 (94.3) 0.079
Current smoker 17 (25.8) 14 (40.0) 0.140
X-ray follow-up duration (mo) 93.3±58.3 119.1±66.9 0.080

Data are expressed as mean±standard deviation or number (%). mSASSS: modified Stoke Ankylosing Spondylitis Spine Score, Dkk1: dickkopf-1, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, BMI: body mass index, TNF: tumor necrosis factor, E2: 17β-estradiol. *Sacroiliitis grade refers to the sum of sacroiliitis grades of the each sides according to the modified New York criteria. Reference ranges for E2 are 0∼400 pg/mL.

J Rheum Dis 2021;28:76~84 https://doi.org/10.4078/jrd.2021.28.2.76
© J Rheum Dis